Destiny Pharma Announces Chief Scientific Officer Dr Bill Love Joins UKRI COVID-19 Research and Innovation Taskforce
Brighton, United Kingdom – 10th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that Dr Bill Love, Chief Scientific Officer of Destiny Pharma, has joined the UK Research and Innovation (“UKRI”) COVID-19 Research and Innovation Taskforce.
On 31st March 2020, UKRI launched a funding call inviting research and innovation proposals to address and mitigate the health, social, economic and environmental impacts of the COVID-19 pandemic. The UKRI Taskforce, which include industry experts such as Dr Love, provides advice and support in the delivery of the UKRI’s COVID-19 research and innovation funding. This will include the identification of future priorities and opportunities for research and innovation projects.
Dr Bill Love, Chief Scientific Officer of Destiny Pharma, said: “I am honoured to join the UKRI Taskforce, created to focus on the strength and creativity of the UK’s world-class research base. I look forward to supporting UKRI in the identification of research and innovation projects to tackle this significant challenge worldwide.”
Destiny Pharma is currently developing with SporeGen Ltd, a novel, biotherapeutic product SPOR-COV for the prevention of COVID-19 and other viral respiratory infections. SPOR-COV utilises the innate immune system with the aim of developing COVID-19 protection within a few days after dosing.
